Efficacy data for risdiplam could position Roche’s oral SMA therapy ahead of Spinraza

Even with a PDUFA delay for Roche’s SMA therapy earlier this month, efficacy data from the Phase II/III FIREFISH trial of risdiplam released Tuesday cast a favorable light on the oral therapy when compared with Biogen’s Spinraza.

Roche (SIX:ROG; OTCQX:RHHBY) and partner PTC Therapeutics Inc. (NASDAQ:PTCT) disclosed in January that risdiplam met the primary endpoint of the FIREFISH trial; it did not provide detailed data at that time (see “Risdiplam Hits Again in FIREFISH”)...